In Vitro Endothelial Progenitor Cell Expansion Using Serum-Free Medium
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell transplantation therapies for ischemic cardiac diseases, such as bone marrow mononuclear cell transplantation and endothelial progenitor cell therapies, face challenges including physical burden on patients, repetitive procedures, and difficulties in securing sufficient qualitatively and quantitatively effective cells for transplantation.
Innovation Solution
A method for expanding functional undifferentiated endothelial progenitor cells in vitro using a serum-free culture medium containing stem cell factor, interleukin-6, FMS-like tyrosine kinase 3 ligand, thrombopoietin, and optionally vascular endothelial growth factor or transforming growth factor β inhibitor, which allows for efficient expansion and differentiation of hemangioblasts into endothelial progenitor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bone marrow mononuclear cell transplantation therapy is applied, then ischemic cardiac diseases can be treated, but physical burden on patients increases due to systemic anesthesia, G-CSF administration, and apheresis procedures
Solution Approach 1:
The invention extracts and expands endothelial progenitor cells in vitro before transplantation, separating the cell expansion process from the patient's body. This allows patients to avoid repeated physical burdens of apheresis and G-CSF administration while still receiving sufficient cells for therapy.
Solution Approach 2:
The invention performs preliminary expansion of endothelial progenitor cells in vitro before actual transplantation. By pre-expanding cells in a controlled laboratory environment using specific growth factors (SCF, IL-6, Flt-3 ligand, TPO), the need for repeated in-vivo stimulation procedures is eliminated.
2Reliability
If repetitive transplantation therapy is performed, then therapeutic effect can be maintained, but patient burden and procedural complexity increase
Solution Approach 1:
The invention enables cells to be expanded and maintained in vitro using defined growth factor combinations, allowing the cell population to self-renew and self-maintain without requiring repeated external stimulation procedures. This reduces procedural complexity while maintaining therapeutic efficacy.
3Quantity of substance
If sufficient cells for transplantation are secured, then therapeutic effect is achieved, but difficulty arises in obtaining qualitatively and quantitatively sufficient cells
Solution Approach 1:
The invention changes the cultivation parameters by using a serum-free medium with specific growth factors (SCF, IL-6, Flt-3 ligand, TPO) and adding VEGF and/or TGF-β inhibitor. This parameter optimization enables efficient in vitro expansion, increasing cell quantity while simplifying the acquisition process from peripheral blood.
Solution Approach 2:
The invention applies local quality enhancement by selectively adding specific growth factors to the culture medium at optimized concentrations. This localized optimization of growth conditions maximizes cell expansion efficiency and maintains cell quality, resolving the difficulty of obtaining sufficient cells.
4Quantity of substance
If cells are expanded in vitro, then sufficient cells for transplantation can be obtained, but differentiation control becomes critical to maintain cell functionality
Solution Approach 1:
The invention uses feedback control through the addition of TGF-β inhibitor, which suppresses unwanted differentiation pathways while maintaining the undifferentiated state of endothelial progenitor cells during expansion. This ensures both sufficient cell quantity and maintained functionality.
Solution Approach 2:
The invention employs a composite culture system combining multiple growth factors (SCF, IL-6, Flt-3 ligand, TPO) with VEGF and/or TGF-β inhibitor in a serum-free medium. This composite approach provides comprehensive control over cell expansion and differentiation, achieving both quantity and quality requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the qualitative and quantitative production of endothelial lineage cells, improving cardiac function in ischemic cardiac diseases, making it a useful approach for cell transplantation therapy targeting vascular disorders.
Implementation Method 1
efficient expansion of EPC in vitro by culturing a hemangioblast in a serum-free culture medium containing a factor selected from the group consisting of (1) a stem cell factor (SCF), (2) interleukin-6 (IL-6), (3) FMS-like tyrosine kinase 3 (Flt-3 ligand) and (4) thrombopoietin (TPO)
Implementation Method 2
cultivation conditions permitting undifferentiated endothelial progenitor cells to differentiate and expand in vitro
Implementation Method 3
more efficient expansion of EPC by further adding (5) a vascular endothelial growth factor (VEGF), and/or (6) a transforming growth factor β (TGF-β) inhibitor to the medium
Data Source
AI summary
The present invention provides a method for expanding an endothelial progenitor cell in vitro. More particularly, the present invention provides a method for culturing a hemangioblast comprising incubating a hemangioblast in a serum-free culture medium containing one or more factors selected from the group consisting of stem cell growth factor, interleukin-6, FMS-like tyrosine kinase 3 and thrombopoietin, and a vascular endothelial cell produced by the method; and a serum-free culture medium containing one or more factors selected from the group consisting of stem cell growth factor, interleukin-6, FMS-like tyrosine kinase 3 ligand and thrombopoietin, and a kit for the preparation of the serum-free culture medium and the like.